Skip to content

Sarcopenic Obesity in Neurodisabilities

Sarcopenic Obesity in Neurodisabled People

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03863379
Acronym
SarcObeNDS
Enrollment
150
Registered
2019-03-05
Start date
2019-05-02
Completion date
2022-05-15
Last updated
2023-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Sclerosis, Sarcopenic Obesity, Spinal Cord Injuries, Stroke, Traumatic Brain Injury

Keywords

Sarcopenia, sarcopenic obesity, stroke, sci, TBI, MS

Brief summary

To describe the frequency and thresholds for sarcopenic obesity in neurodisabled persons and the fat and lean mass distribution based on various neurodisabilities

Interventions

DIAGNOSTIC_TESTwhole body DXA

Measurements of body composition may be used to study how lean body mass and body fat change during health and disease and have provided a research tool to study the metabolic effects of obesity and various wasting conditions. DXA measurements are based in part on the assumption that the hydration of fat-free mass remains constant at 73%.

Sponsors

University of Athens
CollaboratorOTHER
University of Patras
CollaboratorOTHER
Dionyssiotis, Yannis, M.D.
Lead SponsorINDIV

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
20 Years to 90 Years
Healthy volunteers
Yes

Inclusion criteria

Persons with * stroke / cerebrovascular disease * traumatic brain injury * multiple sclerosis * spinal cord injuries (including spinal cord lesions i.e. myelopathies etc.)

Exclusion criteria

Persons with * heterotopic ossifications, * chronic administration of drugs, which promote fat increase * chronic administration of drugs, which promote bone or muscle loss * co-existing other diseases such as: endocrinopathies, muscular dystrophies, non-alcoholic fatty liver disease.

Design outcomes

Primary

MeasureTime frame
Fat and lean mass in neurodisabledan average of 1 year
Frequency of sarcopenic obesityan average of 1 year

Secondary

MeasureTime frame
Body mass index correlation with fat mass and visceral fatan average of 1 year

Countries

Greece

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 11, 2026